Marco Meglio is an Assistant Managing Editor at NeurologyLive. With a focus on medicine and healthcare, he covers a range of topics including gene therapy, immunology, public health, and digital health. Marco has been featured in various publications such as Cliggott Publishing Co, Contagion_Live, and AJMC - The American Journal of Managed Care.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Marco Meglio's coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on neurology-related topics such as clinical trials, multiple sclerosis, Parkinson's disease, and Duchenne muscular dystrophy. His articles frequently cite data and press releases.
Given this focus, Marco may be interested in receiving pitches related to ongoing or upcoming clinical trials in the field of neurology and pharmaceuticals. Pitches that offer access to exclusive data or insights from leading experts within these areas would likely resonate well with him.
As he covers a wide range of scientific themes within healthcare and pharmaceuticals, sources should ensure that their pitches are evidence-based and provide valuable contributions to ongoing research or developments in these fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Marco Meglio
CurePSP and UCSF announced enrollment of the first participant in the PSP Trial Platform, believed to be the first platform trial ever conducted specifically for progressive supranuclear palsy, designed to test multiple investigational drugs simultaneously.
By: Marco Meglio
The FDA has cleared Quantum BioPharma's investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.
The FDA approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.
By: Marco Meglio
A large multicenter study found that APOE genotype and a polygenic Alzheimer risk score together predict up to a 10-year difference in disease onset among people carrying an extra copy of the APP gene, whether through an APP duplication or Down syndrome.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is acute ischemic stroke!
By: Marco Meglio
A large claims-based cohort study found that two doses of the recombinant zoster vaccine reduced the risk of shingles by 64% to 81% in adults with multiple sclerosis, a population with elevated shingles risk and historically low vaccine uptake.
By: Marco Meglio
A phase 3 trial found that solriamfetol significantly improved wakefulness and reduced excessive daytime sleepiness in Chinese patients with obstructive sleep apnea, with a safety profile consistent with prior studies conducted in Western populations.
By: Marco Meglio
The new data from ALKIVIA marks the first phase 3 study to show statistically significant, clinically meaningful improvement in immune-mediated necrotizing myopathy, a subtype with no approved therapy.
By: Marco Meglio
The cerebrovascular neurosurgeon at University Medical Center New Orleans discussed performing the first THUNDERBOLT stroke thrombectomy in the United States and what computer-assisted vacuum thrombectomy offers over traditional aspiration.
By: Marco Meglio
David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.
